查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1223358

流感治疗的全球市场:各类型，各药物，各给药途径，各流通管道，各终端用户地区展望，竞争策略，市场区隔预测(～2032年)

Flu Treatment Market Size- By Types, By Medication, By Route of Administration, By Distribution Channel, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 255 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球流感治疗的市场规模，预计到2032年以5.25％的CAGR成长，达到17亿4,000万美元。技术的持续性进步，对流感治疗的民营企业和政府机关的伙伴关係，医疗费增加，抗病毒药物的研究开发费增加，促进市场成长。

本报告提供全球流感治疗市场相关调查分析，市场动态，市场分析，企业简介等系统性资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
    • 二次资料
    • 一次资料
    • SPER内部资料库
    • KOL的洞察
  • 市场规模的估计
    • Top-Down(由上而下)和Bottom-Up(由下而上)的方法
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球流感治疗市场的COVID-19影响

第5章 市场变数与展望

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术性形势
    • 环境的形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 竞争情形

  • 全球流感治疗的製造地的分布，销售区域，产品类型
  • 全球流感治疗市场合併和收购，伙伴关係，产品的销售，及合作

第7章 全球流感治疗市场(100万美元)(2019年～2032年):各类型

  • 类型A
  • 类型B
  • 类型C

第8章 全球流感治疗市场(100万美元)(2019年～2032年):各药物

  • 抗病毒药物
  • 抗组织胺药物
  • 止痛药
  • 其他

第9章 全球流感治疗市场(100万美元)(2019年～2032年):各给药途径

  • 口服
  • 非口服
  • 其他

第10章 全球流感治疗市场(100万美元)(2019年～2032年):各流通管道

  • 医院药局
  • 线上药局
  • 零售药局

第11章 全球流感治疗市场(100万美元)(2019年～2032年):各终端用户

  • 医院
  • 居家医疗
  • 专门诊所
  • 其他

第12章 全球流感治疗市场(100万美元)(2019年～2032年):各地区

  • 全球流感治疗市场规模与市场占有率(2019年～2025年):各地区
  • 全球流感治疗市场规模与市场占有率(2026年～2032年):各地区
  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的亚太地区
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的欧洲
  • 中东和非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东
  • 北美
    • 加拿大
    • 墨西哥
    • 美国
  • 南美
    • 阿根廷
    • 巴西
    • 其他的南美

第13章 企业简介

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Lilly
  • Merck & Co. Inc.
  • Mylan N.V.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Sanofi

第14章 简称一览

第15章 参照链接

第16章 结论

第17章 调查范围

简介目录
Product Code: HLCA2313

Global Flu Treatment Market Overview

According to SPER Market Research, the Global Flu Treatment Market is estimated to reach USD 1.74 billion by 2032 with a CAGR of 5.25%.

Flu, commonly known as influenza, is a typical viral infection. Chills, aches in the muscles, fever, headaches, runny nose, cough, and others are common flu symptoms. The respiratory tract is primarily impacted by flu. Influenza viruses come in four main categories: influenza A, influenza B, influenza C, and influenza D. The influenza virus types A and B that cause seasonal flu most frequently each year are A and B. The market for influenza treatments has grown due to a number of causes, including an increase in healthcare spending and R&D spending on antiviral drugs. The expansion of government programmes to fight the flu and create reliable tests will support it. The rising cost of creating tests and equipment may restrain industry expansion. The limitations on accessibility and the availability of raw materials raise the cost of the final product.

Impact of COVID-19 on the Global Flu Treatment Market

The global market for flu medications is expanding as a result of ongoing advancements in technology and partnerships between private businesses and governmental agencies for the treatment of such pandemic flu. This is due to the COVID-19 disease, which is spreading continuously throughout the world and causing a significant number of deaths worldwide. Due to the global pandemic COVID-19, which has had a severe impact on a significant section of the population, the hospital pharmacies segment is predicted to exhibit the highest CAGR during the projection period. As a result, it is likely to encourage the market for flu medications to expand.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Type, By Medication, By Route of Administration, By Distribution Channel, By End User.

Regions covered Asia-Pacific, Europe, Middle East and Africa, North America, Latin America

Companies Covered AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GSK plc, Lilly, Merck & Co. Inc., Mylan N.V., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.

Global Flu Treatment Market Segmentation:

By Type: Based on the Type, Global Flu Treatment Market is segmented as; Type A, Type B, and Type C.

By Medication: Based on the Medication, Global Flu Treatment Market is segmented as; Antiviral drugs, Antihistamines, Analgesics, and Others.

By Route of Administration: Based on the Route of Administration, Global Flu Treatment Market is segmented as; Oral, Parenteral, Others

By Distribution Channel: Based on the Distribution Channel, Global Flu Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

By End User: Based on the End User, Global Flu Treatment Market is segmented as; Hospitals, Homecare, Specialty Clinics, Others

By Region: Based on region, The Global Flu Treatment Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to the concentration of international players on cutting-edge technologies, the flu treatment market in North America has seen good growth over the course of the anticipated timeframe. The American healthcare authority also released COVID-19 and flu virus testing recommendations for clinicians.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Flu Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Flu Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Flu Treatment Market

7. Global Flu Treatment Market, By Type, 2019-2032 (USD Million)

  • 7.1. Type A
  • 7.2. Type B
  • 7.3. Type C

8. Global Flu Treatment Market, By Medication, 2019-2032 (USD Million)

  • 8.1. Antiviral drugs
  • 8.2. Antihistamines
  • 8.3. Analgesics
  • 8.4. Others

9. Global Flu Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Others

10. Global Flu Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Global Flu Treatment Market, By End User, 2019-2032 (USD Million)

  • 11.1. Hospitals
  • 11.2. Homecare
  • 11.3. Specialty Clinics
  • 11.4. Others

12. Global Flu Treatment Market, By Region, 2019-2032 (USD Million)

  • 12.1. Global Flu Treatment Market Size and Market Share by Region (2019-2025)
  • 12.2. Global Flu Treatment Market Size and Market Share by Region (2026-2032)
  • 12.3. Asia-Pacific
    • 12.3.1. Australia
    • 12.3.2. China
    • 12.3.3. India
    • 12.3.4. Japan
    • 12.3.5. South Korea
    • 12.3.6. Rest of Asia-Pacific
  • 12.4. Europe
    • 12.4.1. France
    • 12.4.2. Germany
    • 12.4.3. Italy
    • 12.4.4. Spain
    • 12.4.5. United Kingdom
    • 12.4.6. Rest of Europe
  • 12.5. Middle East and Africa
    • 12.5.1. Kingdom of Saudi Arabia
    • 12.5.2. United Arab Emirates
    • 12.5.3. Rest of Middle East & Africa
  • 12.6. North America
    • 12.6.1. Canada
    • 12.6.2. Mexico
    • 12.6.3. United States
  • 12.7. Latin America
    • 12.7.1. Argentina
    • 12.7.2. Brazil
    • 12.7.3. Rest of Latin America

13. Company Profiles

  • 13.1. AstraZeneca
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Bayer AG
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Bristol-Myers Squibb Company
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. F. Hoffmann-La Roche Ltd.
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. GSK plc
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. Lilly
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. Merck & Co. Inc.
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Mylan N.V.
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. NATCO Pharma Limited
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Novartis AG
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Pfizer Inc.
    • 13.11.1. Company details
    • 13.11.2. Financial outlook
    • 13.11.3. Product summary
    • 13.11.4. Recent developments
  • 13.12. Sanofi
    • 13.12.1. Company details
    • 13.12.2. Financial outlook
    • 13.12.3. Product summary
    • 13.12.4. Recent developments
  • 13.13. Sun Pharmaceutical Industries Ltd.
    • 13.13.1. Company details
    • 13.13.2. Financial outlook
    • 13.13.3. Product summary
    • 13.13.4. Recent developments

14. List of Abbreviations

15. Reference Links

16. Conclusion

17. Research Scope